by Daniel Gray | Nov 8, 2013 | Press Release | 0 Comments
November 8, 2013 – New York, NY, and Parma, Italy – CereSpir™ Incorporated and Chiesi Farmaceutici S.p.A. today announced CereSpir has acquired the worldwide development and commercialization rights to CHF 5074, a novel, first-in-class small molecule microglia... read more
by Daniel Gray | Jul 26, 2013 | Press Release | 0 Comments
Patients with Mild Cognitive Impairment treated with CHF 5074 for up to 90 weeks demonstrated highly statistically significant improvements in verbal memory and executive function CHF 5074 is a first-in-class small molecule microglia modulator, the only compound of... read more
by Daniel Gray | Jul 26, 2013 | Press Release | 0 Comments
CHF 5074 is a novel, first-in-class small molecule microglia modulator created by Chiesi Final results of a 14-week, double-blind, placebo-controlled Phase 2 study in 96 MCI patients and interim data from the 90-week open-label extension study indicate CHF 5074... read more